Health care stocks advanced late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each climbing 1.4%.
The iShares Biotechnology ETF (IBB) added 0.9%.
In corporate news, RedHill Biopharma (RDHL) shares rose 5.8% after it said Tuesday it has started patient recruitment for a phase 2 trial of opaganib in combination with darolutamide for the treatment of metastatic castrate-resistant prostate cancer.
AstraZeneca (AZN) Chief Executive Pascal Soriot has spoken privately on a number of occasions of his preference to move the company's stock market listing to the US, The Times reported Tuesday. AstraZeneca gained 2.2%.
IGM Biosciences (IGMS) shares jumped 15% after the firm said it has agreed to be acquired by Concentra Biosciences.
Sage Therapeutics (SAGE) is cutting 338 jobs, or the majority of its workforce, after the biotech company agreed to be acquired by Supernus Pharmaceuticals (SUPN), according to government filings in Massachusetts and media reports. Sage shares were down 0.2%, and Supernus added 0.9%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。